BIH Lecture | Chantal Pichon: "Messenger RNA, a Game Changer in Biomedicine: Where Do We Stand From Now?"
Part of the Lecture Series "Frontiers in Translational Medicine - Scientific and Structural Challenges" on key questions of translation in medicine.
Only available in English.
BIH Lecture
The potential of messenger RNA (mRNA)-based vaccines has been revealed by the success of rapid and adaptable vaccination strategies to fight against COVID-19 pandemic. The achievement of those mRNA vaccines has been made possible through advances in the design of mRNA structure, manufacturing and delivery systems. This success opens up an avenue for the development of innovative mRNA-based formulations envisioning different therapeutic applications in immunotherapy, regenerative medicine and gene editing. Those formulations are quite challenging due to the peculiar nature of mRNA. Current knowledge regarding strategies that we and other have proposed to overcome multiple biological barriers and to obtain a targeted delivery will be summarized. Issues that we have to face when conducting those strategies will be discussed. Last, I will present challenges that have to be tackled to fully prove mRNA mettle for therapeutic applications.
About the Speaker
Chantal Pichon is fill Professor at the University of Orleans (France) and holds the Innovation Chair of Excellence at the Institut Universitaire de France (Paris).She is also BIH Visiting Professor at the BIH Center for Regenerative Therapies (BCRT). She conducts interdisciplinary projects based on chemistry, molecular and cell biology. These last ten years, she has been particularly interested in vaccines and therapeutics based on messenger RNA (mRNA) and is developing innovative formulations for vaccination, protein replacement therapy and cell therapy. Chantal Pichon has patented an mRNA bioproduction technology, a complete paradigm shift from in vitro production and a revolutionary new use of yeast as cell factory. It envisions building an economically sustainable biotechnology process for the production of high-quality therapeutic mRNAs. The goal is to reduce social disparities between and within European countries and around the world that are unfavorably correlated with access to new biopharmaceuticals such as mRNAs.
Registration
Please register here.
Login Information
Login Information
Login via Zoom Webinar
Please note that the login link is not sent out immediately after your registration! You will receive both the evening before the event. You have the following possibilities to participate:- You can download the Zoom Webinar App beforehand (please do so before the lecture starts!)
- You can link in via the Browser (preferably Chrome)
- You can dial in by telephone (you will receive the dial-in number after your registration)
For security reasons, please login to Zoom Webinar with your full name and institution (preferably in abbreviated form).
Discussion via Q&A
The discussion will be held via the Q&A function of Zoom Webinar. If you would like to join the discussion, please type in your question into the Q&A area and moderators will pose the question to the speaker or arrange a dialogue if applicable.
Recording
The BIH Lecture will be recorded for the documentation on our website.
Thank you for your cooperation!
